Endava stock price target lowered to $12 from $16 at TD Cowen

Several prominent investment firms, including TD Cowen, Guggenheim, and Needham, have significantly reduced their price targets for Endava PLC (DAVA), citing lower-than-expected fiscal year 2026 guidance and a challenging services spending environment. TD Cowen, cutting its target to $12 from $16, characterized this as 'another reset' for the stock, which is down over 67% year-to-date, and anticipates shares remaining range-bound until the company demonstrates consistent performance. These adjustments reflect broader concerns over Endava's future growth and its ability to adapt to the evolving generative AI landscape amidst cautious client spending.

Analysis

Multiple analyst downgrades underscore significant near-term headwinds for Endava PLC (DAVA), with TD Cowen, Guggenheim, and Needham all reducing their price targets following weak forward guidance. TD Cowen's reduction to $12.00, characterizing the company's lower-than-expected fiscal year 2026 outlook as "another reset," is particularly notable. This sentiment is reflected in the stock's performance, which has declined over 67% year-to-date. While Endava's most recent Q4 2025 earnings per share of £0.24 slightly exceeded forecasts, the 3.9% year-over-year revenue decline highlights top-line pressure. The core challenge stems from a strategic overhaul of its go-to-market strategy and delivery model, a necessary adaptation to the generative AI landscape and a volatile client spending environment. Analysts expect the stock to remain range-bound, as investor tolerance for negative surprises is low, and the market awaits tangible proof of a successful transition and a return to consistent execution before rewarding the shares.

Key Decisions for Investors

• Given the weak forward guidance and ongoing strategic transition, investors should monitor for evidence of stabilization in revenue and improved outlook in subsequent quarters before considering new or increased positions.
• The stock is likely to remain volatile and range-bound in the near term; patience is required as the market waits for the company to demonstrate consistency following its operational changes.
• Despite the severe price decline, note the divergence in analyst ratings, with Guggenheim and Needham maintaining 'Buy' ratings, suggesting some see long-term value contingent on successful execution of the company's pivot to address AI and macroeconomic pressures.